At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based President operating in the Biotechnology space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Shaun Grady
Vice-President Business Development Operations of AstraZeneca
Shaun Grady has responsibility for Global Business Development at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including externalisation, licensing and partnering, M&A, and divestments. Shaun was appointed to his current role in 2013 with the creation of the Global Product and Portfolio Strategy (GPPS) unit. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10). Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca. Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT), led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ-BMS Diabetes Alliance. In addition, he has spent time in the US business managing the legal function and also completed a two year secondment to HR, leading a global People Strategy change project. Shaun is an Honorary Fellow in Entrepreneurship at Cambridge Judge Business School and is a member of the Board of Cambridge United Football Club and Cambridge Arts Theatre. Based in Cambridge, Shaun enjoys rugby and football, and occasionally turns his hand to sports writing.
Follow Shaun Grady:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Emmanuel Ligner
President & CEO, Life Sciences of GE Healthcare
Emmanuel joined GE Healthcare in April 2008, following its acquisition of Whatman International Plc. Since 2008, Emmanuel has held various positions in GE Healthcare Life Sciences. Working both in the UK and in the US, he managed the North America BioProcess business. In January 2012, Emmanuel took charge of the Commercial part of the then Life Sciences business, across EMEA, later expanding his role to include global commercial leadership of BioProcess. In January 2016, Emmanuel was name General Manager of the Core Imaging business which he held until he was named President and CEO of Life Sciences In July 2017. Emmanuel first entered the biopharma industry in Japan, joining Ostuka Pharmaceutical International Ltd as a Medical Representative in Tokyo. After five years in Ostuka in various roles, Emmanuel joined Abbott Japan, occupying positions such as Marketing Director Diagnostic Division and Commercial Director Diabetes Care Division. After 10 years in Japan, Emmanuel moved to the UK as Vice President Sales & Marketing Europe for Whatman International Plc.
Follow Emmanuel Ligner:
About Cytiva, GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Jan Makela
President and CEO, Imaging at GE Healthcare of GE Healthcare
Jan Makela is the President & CEO of GE Healthcare Global Services. Appointed in December 2017, he oversees the global development and execution of GE Healthcare’s service solutions and operations around the globe.
Follow Jan Makela:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Kieran Murphy
President & CEO of GE Healthcare
Kieran Murphy is President and CEO of GE Healthcare, a $20 billion business unit of General Electric that provides transformational medical technologies and solutions to the global healthcare industry. GE Healthcare supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life-sciences. Prior to this, Kieran was President and Chief Executive Officer of GE Healthcare Life Sciences, a $3.7 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for diagnostics, therapy selection and treatment monitoring in patient care. Kieran was appointed CEO in May 2011 and oversaw significant revenue growth and geographic expansion of the molecular medicine business. Kieran joined GE Healthcare in 2008 from Whatman plc, a $230 million global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Kieran has over twenty years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc.
Follow Kieran Murphy:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Richard Young
Vice President, Vault CDMS of Veeva
Follow Richard Young:
About Veeva: Veeva Systems is a provider of cloud-based business solutions for the global life sciences industry.
Jeanne Bolger
Vice President Venture Investing of Johnson & Johnson Development Corporation
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Follow Jeanne Bolger:
About Johnson & Johnson Development Corporation, Pulmocide: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Alun McCarthy
Vice President of C4X Discovery
Alun has over 30 years of pharmaceutical industry experience, including drug discovery & development, genetics and biomarker research. Alun was co-founder and CEO of both Adorial (in 2014) and of PGXIS (in 2007). Former roles at GlaxoSmithKline include Head of Translational Medicine & Genetics for Psychiatry, Director of Clinical Pharmacogenetics, and Medical Strategy Head for CV/Metabolic Diseases. Alun has managed staff on a global basis, and has significant experience of engaging with regulatory authorities in the US, Europe and Japan. He holds a BA (Biochemistry) from the University of Cambridge, and a PhD (Biochemistry) from Trinity College, Dublin.
Follow Alun McCarthy:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Martin Watson
Vice President of C4X Discovery
Martin was one of the first employees of the Company, coming from AstraZeneca plc where he had worked for 4 years in the industrial application of NMR to drug discovery. He has a first class masters chemistry degree from the University of Birmingham and a PhD from the University of Sheffield. He has applied NMR techniques across a wide range of drug targets.
Follow Martin Watson:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Victoria Kitcatt
Vice President and Assistant General Counsel of Pfizer
Follow Victoria Kitcatt:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Dipankar Bhattacharjee
President & CEO: Generics Europe of Teva Pharmaceutical Industries
Mr. Dipankar Bhattacharjee was appointed President and CEO, Generics Europe in April 2013. Mr. Bhattacharjee joined Teva as Chief Executive Officer, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including Vice President, Commercial in both Europe and Asia-Pacific regions, and Corporate Vice President and President, Asia Pacific Region. Mr. Bhattacharjee began his career at Nestlé SA and Bank of America. Mr. Bhattacharjee received a BA in Economics from St. Stephens College, University of Delhi, and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.
Follow Dipankar Bhattacharjee:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Gareth Jones
Vice President, Intellectual Property of BenevolentAI
Gareth Jones is vice president of intellectual property at BenevolentAI, a company developing and applying artificial intelligence (AI) technology to enhance and accelerate scientific discovery. In this role, Gareth Jones is responsible for all strategic and operational aspects of intellectual property across the BenevolentAI technology and pharmaceutical business units. Gareth Jones started his career in software engineering, holding technical leadership roles at IBM and Vodafone across a variety of cutting-edge technology areas. He initially became involved in intellectual property as an inventor and has more than 20 granted patents. At IBM, Gareth Jones became one of the youngest recipients of the Master Inventor title, in recognition of his sustained innovation leadership through management of invention harvesting and inventor education and mentoring. Following a role managing the global invention harvesting process at Vodafone, Gareth Jones was recruited as head of intellectual property at SwiftKey, an AI technology start-up that was sold to Microsoft in one of the largest UK tech exits of 2015/2016. He built and scaled IP operations, prepared the business for sale and played a key role in facilitating the acquisition. Gareth Jones joined the Microsoft IP team to oversee the SwiftKey integration and provided additional support evaluating patents for licensing, divestiture and prosecution.
Follow Gareth Jones:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Martin Ducker
Vice President of Juvenescence
Follow Martin Ducker:
About Juvenescence: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Anne Prener
President & CEO of Imbria Pharmaceuticals
Anne brings to Freeline over 25 years of experience in drug development and executive leadership across several therapeutic areas, with special focus on rare diseases and gene therapy. Anne most recently served as the CEO of Gyroscope Therapeutics, a preclinical gene therapy company focusing on ophthalmology, where she continues to serve as a non-executive Member of the Board. From 2014-2016, Anne was VP of Clinical Research Haematology and Global Therapeutic Area Head of Haematology in Baxalta, Boston, USA. In this role, she secured several new product approvals (US and EU). Before this, Anne held a number of senior leadership positions in a broad range of functional areas at Novo Nordisk, Denmark, leading global drug development programmes from research to commercialisation, and bringing several products to market globally. Anne has an MD from Copenhagen University and holds a PhD in Epidemiology.
Follow Anne Prener:
About Imbria Pharmaceuticals, Kaleido BioSciences: Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.
Richard Patterson
Vice President, Europe Sales of Molecular Devices
Richard started in his current role in July 2012. He joined Molecular Devices in May 2005 as a Sales Account Manager and progressed through a series of sales management roles of increasing responsibility. Prior to Molecular Devices, Richard was Managing Director of M. J. Patterson (Scientific) Ltd. Richard holds a BSc degree with Honors in Biochemistry from Imperial College, London.
Follow Richard Patterson:
About Molecular Devices: Bioanalytical Systems and Solutions
Richard Patterson
Vice President, Europe Sales of Molecular Devices
Richard started in his current role in July 2012. He joined Molecular Devices in May 2005 as a Sales Account Manager and progressed through a series of sales management roles of increasing responsibility. Prior to Molecular Devices, Richard was Managing Director of M. J. Patterson (Scientific) Ltd. Richard holds a BSc degree with Honors in Biochemistry from Imperial College, London.
Follow Richard Patterson:
About Molecular Devices: Bioanalytical Systems and Solutions
Martin Lachs
Vice President Global Project Management of ICON plc
Follow Martin Lachs:
About ICON plc: ICON is a global provider of outsourced drug development services to biopharma, medical device, biosimilar and generic organizations.
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Christopher Vann
Senior Vice President, Chief Operating Officer of Autolus
Christopher Vann leads commercial activities for Autolus. An industry veteran with 30 years’ experience in both development and business roles, he joined Autolus from Hoffmann-La Roche’s Swiss headquarters, where he was latterly responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has extensive experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level. This includes launching several oncology, immunology and transplant products in countries such as China, Japan, Romania, Russia, South Africa, the UK and the USA. He gained his degree in toxicology and pharmacology from the School of Pharmacy, University of London.
Follow Christopher Vann:
About Autolus: Autolus is in T-cell programming and manufacturing technology.
Gareth Ridge
Senior Vice President of Operations & Site Head of Cambridge Epigenetix
Gareth has a degree in Pharmacology from the University of Cambridge and has worked in the pharmaceutical sector for over 20 years. During his career he has worked for both large and small pharma, biotechnology and clinical research organisations, he also has five years’ experience in business consultancy. In addition to delivering successful clinical research projects Gareth has managed business change projects – including system implementations, process reengineering and organisational change. He has held many leadership positions with responsibility for project and revenue delivery and strategic growth and has had oversight of over 70 clinical research studies, either directly as project manager or as responsible head, and has worked in high growth companies where he successfully built a team to successfully deliver 700% growth in project delivery & revenue in 2 years.
Follow Gareth Ridge:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Joanna Holbrook
Senior Vice President of Research of Cambridge Epigenetix
Joanna started her career in GSK R&D, working for seven years in the UK bioinformatics department, processing the integrating ‘omic data for drug target identification and validation mostly focussing on neurological disease, and then for three years in GSK USA Oncology R&D working on biomarkers for targeted therapies. She then left GSK and the USA for Singapore and built an academic group in A*STAR Singapore Institute for Clinical Sciences. Her group focused on epigenomic trackers of complex disease, especially the interaction of genetic, environmental and disease states in shaping the human epigenome. Her work in Singapore encompassed set-up of observational and interventional cohorts, biobanking, clinical databases, production, processing and analysis of biosample ‘omic profiles and multiple industrial collaborations. Moving back to the UK five years later, she took up a professorship at the University of Southampton, still working on epigenomics and also integration of electronic health record data to clinical cohorts. Most recently she has been VP of Translational Medicine at BenevolentAI, a fast growing British Biotech, where she initiated and led integration of ‘omic data into a large biomedical knowledge graph and machine learning approaches to analyses of patient-level data for precision medicine.
Follow Joanna Holbrook:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Arif Shivji
Senior Vice President, Business and Corporate Development and Development Operations of Drugabilis
Dr Shivji is a co-founder of Ziarco and was previously Vice President of Development Operations and Business Development. Dr Shivji has a broad experience of drug discovery, development and commercialization and has contributed to bringing 10 commercially available products to the market, through various leadership roles in pharmaceutical sciences and global project management. Prior to Ziarco, he was in Pfizer’s Business Development group. In this role, he was responsible for in-licensing, out-licensing and research collaborations with universities, medical research institutions, governments and companies for Pfizer’s Allergy and Respiratory and Anti-Infectives businesses. Dr Shivji has a degree in Pharmacy, and a PhD in Biophysics from the University of Nottingham, under the direction of Professors’ Martyn Davies, Saul Tendler, Clive Roberts and Phil Williams. His post doctoral research was sponsored by Glaxo SmithKline (GSK) Pharmaceuticals and focussed on understanding the role and mechanism of beta amyloid deposition in Alzheimer’s Disease. Dr Shivji has authored and co-authored a number of scientific papers, abstracts and patents and regularly contributes to scientific and business development meetings. He is currently also a visiting professor at the University of Reading.
Follow Arif Shivji:
About Drugabilis: Drugabilis specializes in solid form characterisation and formulation development for human and animal health.
Giles Snare
Vice President , Sales Developed Markets of Beckman Coulter
Follow Giles Snare:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Laurence Tisi
President of ERBA Diagnostics Mannheim
Follow Laurence Tisi:
About ERBA Diagnostics Mannheim, Lumora: ERBA Diagnostics Mannheim is a global in vitro diagnostics company.
Philip M. Toleikis
President & CEO of Sernova
Dr. Toleikis is President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development – Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. While at Sernova, Dr. Toleikis has secured over $60 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN and University of Miami for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies. Dr. Toleikis is an author of over 100 patent applications ande issued patents, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.
Follow Philip M. Toleikis:
About Sernova: Sernova develops regenerative medicine therapeutic technologies for treatment of chronic metabolic diseases.
Lindsay Edwards
Chief Technology Officer and President of Platform of Relation Therapeutics
Lindsay Edwards is the Chief Technology Officer and President of Platform of Relation Therapeutics.
Follow Lindsay Edwards:
About GlaxoSmithKline, Relation Therapeutics: Relation Therapeutics engages in humanizing drug discovery and development.
Campbell Bunce
Senior Vice-President of Scientific Operations of Abzena
Campbell has over 19 years’ experience working in the biotech and diagnostics sectors, occupying senior management positions with Piramed Pharma (Director, Development Programmes), Immune Targeting Systems (R & D Director) and Oxford Immunotec (General Manager, Immunology Products). He has extensive experience in developing novel biologics and vaccines for cancer, inflammatory and infectious diseases, leading them through development and regulatory processes including pre-clinical evaluation and translation in the clinic. Campbell has a PhD in Immunology from the University of Manchester and has published a number of papers in T cell biology, immunomodulators and vaccines.
Follow Campbell Bunce:
About Abzena: Abzena provides complementary services to organizations involved in the development of bio-pharmaceuticals.
Benjamin T Dake
President & Founder of Aerovate Therapeutics
Ben Dake has 15 years experience as an Entrepreneur, Scientist and Biotech Investor. He founded Aerovate to develop therapies with the potential to meaningfully change the treatment of rare diseases. Informed by his training in diseases of aberrant proliferation he views PAH drug development through a unique lens focusing Aerovate on anti-proliferative therapies that directly address the root cause of disease.
Follow Benjamin T Dake:
About Aerovate Therapeutics: Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Nick Child
Vice President of Stablepharma Ltd
Nick Child – Vice President & Co Founder Experienced company leader, business developer, multi-disciplined & experienced in UK & International markets, manufacturing & distribution. Initiated various start-ups, acquisitions, & funding rounds.
Follow Nick Child:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Debasish Talukdar
President, Global Head of Advisory of Prescient Healthcare Group
Follow Debasish Talukdar:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Rakesh Verma
President of Prescient Healthcare Group
Rakesh is the President of our EMEA and APAC businesses. After earning a degree in veterinary medicine, he completed his Master’s and doctoral degrees in immunology at Imperial College, School of Medicine, London. He was then recruited by oncology biotech firm Antisoma, which specialized in the development and out-licensing of monoclonal antibodies. He joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.
Follow Rakesh Verma:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Noor Shaker
Senior Vice President and General Manager of X-Chem
Noor was an assistant professor at Aalborg University in Copenhagen working on machine learning. She has more than 50 publications and 1100+ citations and has co-authored a book on generative methods.
Follow Noor Shaker:
About Lynura, X-Chem: X-Chem, Inc. is a privately held biotechnology company.
Clive Morris
President & Chief Executive Officer of Inivata
Follow Clive Morris:
About Inivata: Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Martin Tangney
Founder and President of Celtic Renewables
Internationally recognised expert in microbial biofuel production, particularly biobutanol. Professor Tangney is Director of the Biofuel Research Centre at Edinburgh Napier University, which conducted the innovative research to develop the fermentation technology being commercialised by Celtic Renewables. Martin advises the Scottish Government on biofuels, and represents the government on its MOU with India on Renewable Energy. Martin is a prominent international speaker in the biofuel area and regularly features in the media, and his international profile, domain expertise and connections will be hugely beneficial to Celtic Renewables Ltd.
Follow Martin Tangney:
About Celtic Renewables: Celtic Renewables is a biofuel startup focused on the renewable energy and whisky sector.
Lynn Purkins
Vice President & Chief Development Officer of Ziarco
Lynn Purkins is the vice president of clinical operations for Reneo Pharmaceuticals. Lynn has nearly three decades of drug development experience in large and small biotechnology companies. Before joining Reneo, Lynn was a founder and chief development officer at Ziarco Pharma, which was acquired by Novartis in 2017. Prior to Ziarco, Lynn held numerous roles at Pfizer, including clinical pharmacology, clinical operations and team leader for projects from target selection to clinical proof of concept. Her experience spans multiple therapeutic areas including dermatology, pain, respiratory and gastroenterology. Lynn received a Ph.D. in nutrition and immunology from University of Leeds and a B.S. in dietetics from Leeds Beckett University.
Follow Lynn Purkins:
About Ziarco: Ziarco develops therapeutic agents for treating inflammatory and allergic diseases.
Jim Knight
President of xRapid
Follow Jim Knight:
About xRapid: xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Tony Brown
Vice President of Scientific and Corporate Development of Asterand
Tony has been with Asterand Bioscience for 16 years. Prior to taking up his current position, he held a number of senior positions within the company including General Manager for the UK Services business, General Manager for the Detroit-based tissue products business and VP, Strategic Alliances, with responsibility for securing and managing the Company’s human tissue supply collaborations. Tony began his career teaching physiology at Nottingham University Medical School in the UK, after obtaining degrees in engineering, bioengineering and a PhD in physiology. He subsequently joined SmithKline Beecham in 1988, where he headed up the receptor pharmacology group within neurosciences research, and led several drug discovery projects and drug screening programs. Tony joined Pharmagene (now Asterand Bioscience) in 1998. Tony has published on the pharmacology and biochemistry of ion and neurotransmitter transport and on the use of human tissues for research in drug discovery and development.
Follow Tony Brown:
About Asterand: Asterand Bioscience is the leading global provider of high quality, well characterized human tissue & human tissue-based research solution.
Robert Spavin
Vice President of Legal Affairs of Virttu Biologics
Robert joined VIRTTU in 2003 as Legal Counsel responsible for the company’s legal and intellectual property affairs. Qualifying as a solicitor with City of London firm Herbert Smith in 1996, he subsequently specialised in IP law at leading IP firm Bird & Bird. He is experienced in the development of growth technology companies, patent management and regulatory affairs.
Follow Robert Spavin:
About Virttu Biologics: Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer.
Alex Graham
Vice President of Translational Medicine of Virttu Biologics
Dr. Alex Graham has more than 30 years of experience as a scientist in the biotechnology and pharmaceutical sector, having most recently worked as a Principal Scientist for AstraZeneca. He has led several small molecule discovery projects and most recently was responsible for the Genomics Facility for AstraZeneca Oncology. He was also responsible for introducing relevant new technologies into the Oncology business, specifically in the areas of biomarkers and translational medicine. Alex joined Virttu in 2008 and has been closely involved in the planning,management and analysis of Virttu’s clinical studies.
Follow Alex Graham:
About Virttu Biologics: Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer.
David Freedman
COO and President of Nanoview Biosciences
Follow David Freedman:
About Nanoview Biosciences: Nanoview Biosciences is developing proprietary products that support research, translation and delivery of precision medicine.
Andrew Sinclair
President and Founder of Biopharm Services
Follow Andrew Sinclair:
About Biopharm Services: Biopharm develop technology solutions and services for the biopharmaceutical manufacturing business, and manufacturing strategy.
Alfredo Boni
Founder & President of Creabilis
Alfredo Boni was the CEO of a large service company, Boni S.p.A, which has operated since 1964 across Europe within many industries in the field of general maintenance, cleaning and sterilization. He was also the founder of a consortium of more than 150 companies devoted to global service for various institutions including hospitals. His industrial, financial and administrative experience in founding and acquiring companies and his entrepreneurial spirit are now being devoted to the world of biotechnology.
Follow Alfredo Boni:
About Creabilis: Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.
